DOP2016000335A - Anticuerpos anti-tau humanizados - Google Patents

Anticuerpos anti-tau humanizados

Info

Publication number
DOP2016000335A
DOP2016000335A DO2016000335A DO2016000335A DOP2016000335A DO P2016000335 A DOP2016000335 A DO P2016000335A DO 2016000335 A DO2016000335 A DO 2016000335A DO 2016000335 A DO2016000335 A DO 2016000335A DO P2016000335 A DOP2016000335 A DO P2016000335A
Authority
DO
Dominican Republic
Prior art keywords
disease
chain variable
variable region
tauopathy
antibody
Prior art date
Application number
DO2016000335A
Other languages
English (en)
Inventor
West Tim
S Athwal Diljeet
d jones Timothy
J Carr Francis
George Edward Holgate Robert
Original Assignee
C2N Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C2N Diagnostics Llc filed Critical C2N Diagnostics Llc
Publication of DOP2016000335A publication Critical patent/DOP2016000335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o fragmento de unión a antígeno que se une específicamente a tau, en donde el anticuerpo o fragmento comprende una región variable de cadena pesada (VH) y una región variable de cadena liviana (VL) que tiene las secuencias de aminoácidos detalladas en la presente. Los anticuerpos o fragmentos de unión a antígeno de la presente invención son útiles para la fabricación de medicamentos para prevenir o tratar la tauopatía. La tauopatía puede ser uno o más de enfermedad de Alzheimer (AD), parálisis supranuclear progresiva (PSP), degeneración corticobasal (CBD), enfermedad de Pick (PiD), un grupo de trastornos relacionados que se denominan colectivamente como demencia frontotemporal con Parkinsonismo ligado al cromosoma 17 (FTDP-17), esclerosis lateral amiotrófica (ALS), enfermedad de Creutzfeldt-Jakob (CJD), demencia pugilística (DP), enfermedad de Gerstmann-Straussler-Scheinker (GSSD), enfermedad de cuerpos de Lewy, encefalopatía traumática crónica (CTE), o enfermedad de Huntington.
DO2016000335A 2014-06-27 2016-12-26 Anticuerpos anti-tau humanizados DOP2016000335A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462018436P 2014-06-27 2014-06-27
US201462080903P 2014-11-17 2014-11-17
US201562170036P 2015-06-02 2015-06-02
PCT/US2015/038002 WO2015200806A2 (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies

Publications (1)

Publication Number Publication Date
DOP2016000335A true DOP2016000335A (es) 2017-04-17

Family

ID=54938957

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000335A DOP2016000335A (es) 2014-06-27 2016-12-26 Anticuerpos anti-tau humanizados

Country Status (27)

Country Link
US (2) US9957317B2 (es)
EP (1) EP3182987B1 (es)
JP (3) JP6626892B2 (es)
KR (1) KR102431596B1 (es)
CN (1) CN106659759B (es)
AU (2) AU2015279643B2 (es)
BR (1) BR112016030686A2 (es)
CA (2) CA3094638A1 (es)
CL (1) CL2016003346A1 (es)
CR (1) CR20170026A (es)
DO (1) DOP2016000335A (es)
EC (1) ECSP17005649A (es)
ES (1) ES2959528T3 (es)
IL (3) IL249734B (es)
MA (1) MA40229A (es)
MX (2) MX384790B (es)
MY (1) MY184540A (es)
NZ (1) NZ727919A (es)
PE (1) PE20170665A1 (es)
PH (2) PH12016502608A1 (es)
RU (1) RU2743152C2 (es)
SG (2) SG11201610862VA (es)
TW (3) TW202136296A (es)
UA (1) UA122771C2 (es)
UY (1) UY36194A (es)
WO (1) WO2015200806A2 (es)
ZA (1) ZA201608875B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
WO2016201434A2 (en) * 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
LT3445785T (lt) 2016-04-18 2022-10-10 Faron Pharmaceuticals Oy Humanizuoti anti clever-1 antikūnai ir jų naudojimas
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022673A1 (en) * 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EP3487524A4 (en) * 2016-07-20 2020-03-25 Anahit Ghochikyan HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
IL311841B2 (en) * 2016-09-10 2025-11-01 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity fortreatment of " disease and injury of the cns
RU2019112860A (ru) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
MX2019011423A (es) 2017-03-28 2019-11-01 Genentech Inc Metodos de tratamiento de enfermedades neurodegenerativas.
KR102784294B1 (ko) * 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
MA50629A (fr) 2017-10-02 2021-03-31 Merck Sharp & Dohme Composés monobactames de chromane pour le traitement d'infections bactériennes
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US20210015865A1 (en) 2018-03-28 2021-01-21 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
EP3830119B1 (en) 2018-08-01 2025-11-12 Imcheck Therapeutics Anti-btn3a antibodies and their use in treating cancer or infectious disorders
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
CA3135170A1 (en) * 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB2600599B (en) * 2019-07-15 2025-05-21 Adel Inc Anti-Tau antibody and use thereof
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
BR112022020753A2 (pt) * 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau
US12624095B2 (en) * 2020-05-26 2026-05-12 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological tau, and methods of detection thereof
EP4171633A1 (en) 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
CN115724970B (zh) * 2022-07-27 2023-10-20 生工生物工程（上海）股份有限公司 一种特异性结合e-cad多肽的结合蛋白及其应用
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116375857A (zh) * 2023-03-30 2023-07-04 天津鸿宇泰生物科技有限公司 一种用于检测Tau蛋白的单链抗体及其制备方法和应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO884368L (no) 1987-10-02 1989-04-03 Du Pont Immunanalyse ved anvendelse av igg-innfangelsesantistoff og multippel, monoklonalt antistoffpaavisningssystem.
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
DK0610330T3 (da) 1991-10-25 1998-01-26 Innogenetics Nv Monoklonale antistoffer mod microtubulus-associeret protein tau
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
US6121003A (en) 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
CN1325491A (zh) 1998-09-08 2001-12-05 基因创新有限公司 作为早期CNS损伤标记物的τ
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
JP4582874B2 (ja) 2000-07-13 2010-11-17 富士通株式会社 偏波モード分散補償方法および偏波モード分散補償装置
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
WO2003057881A1 (en) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
JP4414332B2 (ja) 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
ES2352668T3 (es) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20070224635A1 (en) * 2004-01-30 2007-09-27 Maxygen Holdings, Ltd. Regulated Stop Codon Readthrough
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
CA2598321A1 (en) 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
JP2009506302A (ja) 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EA020324B1 (ru) * 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
NZ588555A (en) 2008-04-24 2012-06-29 Bristol Myers Squibb Co Use of epothilone d in treating tau-associated diseases including alzheimer's disease
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
PL2342226T3 (pl) * 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
WO2010096751A1 (en) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
DK2388871T3 (da) 2009-06-17 2021-02-15 Fujikura Ltd Multibeklædt optisk fiber, optisk fibermodul, fiberlaser og fiberforstærker
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
WO2011045166A1 (en) 2009-09-24 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
US9028830B2 (en) * 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
PE20140218A1 (es) 2010-10-07 2014-03-01 Ac Inmune S A Composicion farmaceutica
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
WO2013063086A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
EP2755688A4 (en) * 2011-10-27 2014-08-06 Nkt Therapeutics Inc HUMANIZED ANTIBODIES AGAINST INKT
PT2794654T (pt) 2011-12-20 2019-09-10 Janssen Biotech Inc Anticorpos anti-phf-tau e suas utilizações
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
BR112014029566A2 (pt) 2012-05-31 2017-07-25 Univ Osaka City agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
DK2885010T3 (da) * 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
WO2014031697A2 (en) 2012-08-21 2014-02-27 The Institute Of Molecular Medicine COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP4356927A3 (en) 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014089104A1 (en) * 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20201422T1 (hr) 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Also Published As

Publication number Publication date
JP2020054356A (ja) 2020-04-09
IL249734A0 (en) 2017-02-28
US20170058024A1 (en) 2017-03-02
TW202136296A (zh) 2021-10-01
MX2017000205A (es) 2017-08-22
TWI664190B (zh) 2019-07-01
IL273656B (en) 2022-01-01
UY36194A (es) 2016-01-29
EP3182987B1 (en) 2023-09-27
AU2021204800A1 (en) 2021-08-05
IL288649A (en) 2022-02-01
KR102431596B1 (ko) 2022-08-12
AU2015279643A1 (en) 2017-01-19
AU2015279643B2 (en) 2021-04-08
MX2021008888A (es) 2021-08-19
TWI734975B (zh) 2021-08-01
TW201607956A (zh) 2016-03-01
CA3094638A1 (en) 2015-12-30
UA122771C2 (uk) 2021-01-06
SG11201610862VA (en) 2017-01-27
WO2015200806A2 (en) 2015-12-30
CL2016003346A1 (es) 2017-07-21
PE20170665A1 (es) 2017-06-10
MX384790B (es) 2025-03-14
US20180371066A1 (en) 2018-12-27
NZ727919A (en) 2021-07-30
EP3182987A2 (en) 2017-06-28
IL249734B (en) 2020-03-31
BR112016030686A2 (pt) 2017-10-31
CN106659759A (zh) 2017-05-10
PH12021550023A1 (en) 2021-12-13
CA2953809A1 (en) 2015-12-30
ECSP17005649A (es) 2018-04-30
CA2953809C (en) 2020-09-29
IL273656A (en) 2020-05-31
EP3182987C0 (en) 2023-09-27
ZA201608875B (en) 2017-09-27
CN106659759B (zh) 2022-04-15
US9957317B2 (en) 2018-05-01
RU2017102514A3 (es) 2019-02-25
RU2017102514A (ru) 2018-07-31
MA40229A (fr) 2021-06-02
TW201946931A (zh) 2019-12-16
JP2017521097A (ja) 2017-08-03
JP6626892B2 (ja) 2019-12-25
PH12016502608A1 (en) 2017-04-24
JP2022050392A (ja) 2022-03-30
SG10201914067XA (en) 2020-03-30
EP3182987A4 (en) 2018-01-24
CR20170026A (es) 2017-06-16
ES2959528T3 (es) 2024-02-26
RU2743152C2 (ru) 2021-02-15
MY184540A (en) 2021-04-01
WO2015200806A3 (en) 2016-02-25
KR20170026390A (ko) 2017-03-08

Similar Documents

Publication Publication Date Title
UY36194A (es) Anticuerpos anti-tau humanizados
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
ECSP18002644A (es) Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos
ECSP19005417A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
JO3692B1 (ar) عوامل، استخدامات وطرق لعلاج مرض تنكسي عصبي
PE20190261A1 (es) Anticuerpos que reconocen tau
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2016006232A (es) Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
MX380937B (es) Anticuerpos dobles especificos.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
PH12019502298A1 (en) Monoclonal antibody to pd-l1
UA123202C2 (uk) Антитіло до тау-білка і його застосування
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
GEP20227382B (en) Anti-coagulation factor xi antibodies
BR112017022073A2 (pt) método para purificação de proteína
PE20181176A1 (es) Composiciones biofarmaceuticas
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX389687B (es) Inmunoglobulinas conjugadas en cys80.
CO2018010286A2 (es) Método para la purificación de proteínas
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra